Spots Global Cancer Trial Database for Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Official Title: A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Study ID: NCT02101593
Conditions
Interventions
Study Description
Brief Summary: Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Contact Details
Name: Ghassan Abou-Alfa, MD
Affiliation: Memorial Sloan-Kettering Cancer Center (MSKCC)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
